Researchers evaluated the prevalence of co-infection and intra-host recombination in over 2 million global SARS-CoV-2 cases and developed strategies for accurate identification and analysis of recombinant strains.
The US could upend biopharma manufacturing. WuXi rivals have an opening
In Congress, influential lawmakers see a Chinese government threat to the US biotech sector. In the competitive world of biopharma manufacturing, companies see an opportunity.